MCL1 and leukemia: Bypassing the MCL-1 resistance mechanism has also been investigated with the pan-histone deacetylase inhibitor panobinostat, which was demonstrated to upregulate Bim, resulting in sustained Bim levels in the presence of venetoclax and a synergistic anti-leukemia effect in AML cell lines and patient samples (40).